Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Apremilast, sold under the brand name Otezla among others, is a medication for the treatment of certain types of psoriasis and psoriatic arthritis. The drug acts as a selective inhibitor of the enzyme phosphodiesterase 4 (PDE4). It is taken by mouth.
History, Community, Culture & Applications
Explore the main themes, entities and connections around Apremilast. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
treatment otezla psoriasis arthritis enzyme psoriatic others us indicated european use pde4 hours mouth adults plaque associated union drug celgene
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Apremilast | 3D model (JSmol) | Interactive image | 1.00 | infobox |
| Apremilast | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Apremilast | ATC code | L04AA32 (WHO) | 1.00 | infobox |
| Apremilast | Bioavailability | 73%; Tmax = ~2.5 hours | 1.00 | infobox |
| Apremilast | CAS Number | 608141-41-9 | 1.00 | infobox |
| Apremilast | ChEBI | CHEBI:78540 | 1.00 | infobox |
| Apremilast | ChEMBL | ChEMBL514800 | 1.00 | infobox |
| Apremilast | ChemSpider | 9736448 | 1.00 | infobox |
| Apremilast | CompTox Dashboard (EPA) | DTXSID30976289 | 1.00 | infobox |
| Apremilast | DrugBank | DB05676 | 1.00 | infobox |
| Apremilast | ECHA InfoCard | 100.234.786 | 1.00 | infobox |
| Apremilast | Elimination half-life | 6–9 hours | 1.00 | infobox |
| Apremilast | Excretion | Urine (58%), faeces (39%) | 1.00 | infobox |
| Apremilast | Formula | C22H24N2O7S | 1.00 | infobox |
| Apremilast | KEGG | D08860 | 1.00 | infobox |
| Apremilast | Legal status | AU: S4 (Prescription only) | 1.00 | infobox |
| Apremilast | Legal status | UK: POM (Prescription only) | 1.00 | infobox |
| Apremilast | Legal status | US: ℞-only | 1.00 | infobox |
| Apremilast | Legal status | EU: Rx-only | 1.00 | infobox |
| Apremilast | Legal status | In general: ℞ (Prescription only) | 1.00 | infobox |
| Apremilast | License data | US DailyMed: Apremilast | 1.00 | infobox |
| Apremilast | MedlinePlus | a614022 | 1.00 | infobox |
| Apremilast | Metabolism | Liver (CYP3A4, with minor contributions from CYP2A6, CYP1A2) | 1.00 | infobox |
| Apremilast | Metabolites | O-desmethylapremilast glucuronide (and others) | 1.00 | infobox |
| Apremilast | Molar mass | 460.50 g·mol−1 | 1.00 | infobox |
| Apremilast | Other names | CC-10004 | 1.00 | infobox |
| Apremilast | Pregnancy category | AU: B3 | 1.00 | infobox |
| Apremilast | Pronunciation | /əˈprɛmɪlæst/ ə-PREM-i-last | 1.00 | infobox |
| Apremilast | Protein binding | c. 68% | 1.00 | infobox |
| Apremilast | PubChem CID | 11561674 | 1.00 | infobox |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.